Phase I Safety Study of Inhaled N-IP-00001 to Determine Tolerability and Safety in Healthy Volunteers.

NCT06662019 ↗

Phase 1 Completed 8 enrolled NeoTrials Pty Ltd

RandomizedSequentialQuadruple-blindTreatment

Summary

Randomized, double-blind, placebo-controlled, dose-escalation Phase I safety study of inhaled N-IP-00001, to determine tolerability and safety in healthy volunteers.

Timeline

Start: 2024-10-29
Primary completion: 2025-01-15
Completion: 2025-01-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	N-IP-00001	Unknown	0.5 mg/ml	Inhaled
Subject	N-IP-00001	Unknown	16 mg/ml	Inhaled

Indications

No indication recorded.